B4GALT7

Across TCGA pan-cancer cohorts, B4GALT7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated B4GALT7 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher B4GALT7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated B4GALT7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where B4GALT7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.674	1.000	.007	31	view →
LSCC	OS	Median	All	0.731	0.907	.013	6	view →
PDAC	DFS	Tertile	III,IV	0.848	0.234	.024	6	view →
LUAD	DFS	Median	II,III,IV	0.220	0.790	.005	6	view →
HNSC	DFS	Quartile	IV	1.000	0.630	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

B4GALT7–CCRCC (OS)

Open the CCRCC breakdown →